IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study (IMMUNOSABR2)
Stereotactic Ablative Body Radiotherapy (SABR) Combined with Immunotherapy (L19-IL2) in Stage IV NSCLC Patients, ImmunoSABR: a Multicentre, Randomised Controlled Open-label Phase II Trial
Sponsor: Academisch Ziekenhuis Maastricht
Terminated
This trial is not transitioning to the Clinical Trial Regulation (CTR) EU No 536/2014.
Other terminated trials from Academisch Ziekenhuis Maastricht
Other Metastatic Disease trials with similar outcome
A PHASE2 clinical study on Metastatic Disease and NSCLC Stage IV, this trial is terminated or withdrawn. The trial is conducted by Academisch Ziekenhuis Maastricht and has accumulated 11 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 6 earlier versions
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Jan 2024 — May 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Jan 2024 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
May 2020 — Nov 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — May 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Academisch Ziekenhuis Maastricht
- Catholic University of the Sacred Heart
- Centre Oscar Lambret
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Erasmus Medical Center
- Gasthuis Zusters Antwerpen
- Heidelberg University
- Institut du Cancer de Montpellier - Val d'Aurelle
- KU Leuven
- Maastricht University Medical Center
- The Netherlands Cancer Institute
- University College, London
- University Ghent
- University Hospital Dresden
- University Hospital Tuebingen
- University Medical Center Nijmegen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Brussels, Belgium , Dresden, Germany , Ghent, Belgium , Heidelberg, Germany , Leuven, Belgium , Lille, France , London, United Kingdom , Maastricht, Netherlands , Montpellier, France and 5 more locations